疏血通注射液联合依达拉奉治疗急性缺血性脑梗死患者的临床探讨

Clinical study of Shuxuetong injection combined with Edaravone on patients with acute ischemic infraction

目的:探讨分析疏血通注射液联合依达拉奉治疗急性缺血性脑梗死患者的临床效果。方法:选取急性脑梗死患者77例,按照随机的方法分为对照组和观察组。对照组患者(39例),除了给予对症支持治疗外,再给予疏血通注射液进行治疗;观察组患者(38例),在对照组的基础上加用依达拉奉治疗。对比两组患者的临床疗效。结果:两组患者的有效率差别显著(P<0.05);观察组患者不良反应事件发生率显著低于对照组(P<0.05)。结论:疏血通注射液联合依达拉奉治疗急性脑梗死患者的效果明确,安全性较好。

Objective:To investigate clinical effects of Shuxuetong injection combined with Edaravone on patients with acute ischemic infarction. Methods:77 ischemic infarction patients were recruited and randomly classified into 2 groups:Shuxuetong injec-tion group (control group, n=39, receiving symptomatic supportive treatment and Shuxuetong injection), and Shuxuetong injection plus Edaravone group ( experimental group, n=38, receiving symptomatic supportive treatment, Shuxuetong injection, and Edara-vone) . Then, the clinical effects of the two groups were compared. Results:There was a significant difference in the effective rate of the two groups (P<0. 05). The incidences of adverse events of experimental group were significantly lower than those of control group (P<0. 05). Conclusions:The application of Shuxuetong injection combined with Edaravone can be more effective in the treatment of the patients with acute ischemic infarction and has a higher safety.